Silica-coated papillomavirus-based nanoparticles: a shielded scaffold for HIV-1 vaccines

Yu Wang; Kathrin Kostka-Wirtz; Nils Bartelsen; Kateryna Loza; Christoph Weingärtner; Philipp Arnold; Dominik Damm; Klaus Überla; Matthias Epple; Vladimir Temchura

doi:10.1039/d5bm01792k

January 1, 2026Biomaterials ScienceOpen Access

Silica-coated papillomavirus-based nanoparticles: a shielded scaffold for HIV-1 vaccines

View Full Paper

Ask AI

Bookmark

Share

Key Points

To explore the use of silica-coated papillomavirus-based nanoparticles for HIV-1 vaccine delivery.
Utilized silica-coated nanoparticles for the formulation of an HIV-1 vaccine.
Assessed safety and efficacy of the nanoparticle platform.
Conducted immunological analyses to evaluate vaccine response.
Demonstrated enhanced delivery of HIV-1 antigens using nanoparticle technology.
Indicated improved immune responses in preclinical models with silica-coated papillomavirus.
Showed potential for developing a more effective HIV-1 vaccine.

Implication

Vaccine platform using nanoparticles improves HIV-1 targeting, suggesting potential for effective immunization.

Abstract

The development of a safe, effective, and accessible human immunodeficiency virus 1 (HIV-1) vaccine remains a global priority, and nanoparticles (NPs) have emerged as a promising platform for vaccine delivery....

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69fa8eac04f884e66b53102c https://doi.org/10.1039/d5bm01792k

View Full Paper

Ask AI

Bookmark

Share

Silica-coated papillomavirus-based nanoparticles: a shielded scaffold for HIV-1 vaccines

Key Points

Implication

Abstract

Discussion

Cite This Study

Silica-coated papillomavirus-based nanoparticles: a shielded scaffold for HIV-1 vaccines

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading